Literature DB >> 15019431

Amphetamine neurotoxicity: accomplishments and remaining challenges.

Una D McCann1, George A Ricaurte.   

Abstract

In addition to the social, cultural and indirect medical complications of amphetamine analog abuse, this class of drugs is also known to have the potential to damage brain monoaminergic cells directly. Using methamphetamine as a prototype, this article provides a brief review of the history of amphetamine neurotoxicity research and the progress that has been made toward defining its characteristics. Remaining challenges for this line of investigation are outlined, and suggested avenues for addressing these challenges are provided.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019431     DOI: 10.1016/j.neubiorev.2003.11.003

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  44 in total

1.  Dopaminergic system dysfunction in recreational dexamphetamine users.

Authors:  Anouk Schrantee; Lena Václavů; Dennis F R Heijtel; Matthan W A Caan; Willy Gsell; Paul J Lucassen; Aart J Nederveen; Jan Booij; Liesbeth Reneman
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

2.  Investigation of the mechanisms mediating MDMA "Ecstasy"-induced increases in cerebro-cortical perfusion determined by btASL MRI.

Authors:  J Rouine; M E Kelly; C Jennings-Murphy; P Duffy; I Gorman; S Gormley; C M Kerskens; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2014-11-01       Impact factor: 4.530

3.  Differentiating prenatal exposure to methamphetamine and alcohol versus alcohol and not methamphetamine using tensor-based brain morphometry and discriminant analysis.

Authors:  Elizabeth R Sowell; Alex D Leow; Susan Y Bookheimer; Lynne M Smith; Mary J O'Connor; Eric Kan; Carly Rosso; Suzanne Houston; Ivo D Dinov; Paul M Thompson
Journal:  J Neurosci       Date:  2010-03-17       Impact factor: 6.167

4.  Mirtazapine to reduce methamphetamine use: a randomized controlled trial.

Authors:  Grant N Colfax; Glenn-Milo Santos; Moupali Das; Deirdre McDermott Santos; Tim Matheson; James Gasper; Steve Shoptaw; Eric Vittinghoff
Journal:  Arch Gen Psychiatry       Date:  2011-11

5.  [Metamphetamine].

Authors:  Y Alvarez; A Cabrero; S Abanades; M Farré
Journal:  Aten Primaria       Date:  2005-05-31       Impact factor: 1.137

6.  Nrf2 gene deletion fails to alter psychostimulant-induced behavior or neurotoxicity.

Authors:  Alejandra M Pacchioni; Joseph Vallone; Roberto I Melendez; Andy Shih; Timothy H Murphy; Peter W Kalivas
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

Review 7.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

Review 8.  Neuroimaging of children following prenatal drug exposure.

Authors:  Chris Derauf; Minal Kekatpure; Nurunisa Neyzi; Barry Lester; Barry Kosofsky
Journal:  Semin Cell Dev Biol       Date:  2009-03-13       Impact factor: 7.727

9.  Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice.

Authors:  J P Q Zhu; W Xu; J A Angulo
Journal:  Neuroscience       Date:  2006-05-02       Impact factor: 3.590

10.  The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2007-11-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.